Evidence map›Paper›PMID 37764425›Full record

ArticleMolecules (Basel, Switzerland)2023

Development of Masitinib Derivatives with Enhanced M

Cintia A Menendez, Adil Mohamed, Gustavo R Perez-Lemus, Adam M Weiss, Benjamin W Rawe, Guancen Liu, Alex E Crolais, Emma Kenna, Fabian Byléhn, Walter Alvarado and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Cintia A MenendezPritzker School of Molecular Engineering, University of Chicago, 5640 South Ellis Avenue, Chicago, IL 60637, USA.
Adil MohamedPritzker School of Molecular Engineering, University of Chicago, 5640 South Ellis Avenue, Chicago, IL 60637, USA.
Gustavo R Perez-LemusPritzker School of Molecular Engineering, University of Chicago, 5640 South Ellis Avenue, Chicago, IL 60637, USA.ORCID 0000-0002-8650-8467
Adam M WeissDepartment of Chemistry, University of Chicago, 5735 South Ellis Avenue, Chicago, IL 60637, USA.ORCID 0000-0002-4972-1402
Benjamin W RawePritzker School of Molecular Engineering, University of Chicago, 5640 South Ellis Avenue, Chicago, IL 60637, USA.
Guancen LiuDepartment of Chemistry, University of Chicago, 5735 South Ellis Avenue, Chicago, IL 60637, USA.
Alex E CrolaisDepartment of Chemistry, University of Chicago, 5735 South Ellis Avenue, Chicago, IL 60637, USA.
Emma KennaPritzker School of Molecular Engineering, University of Chicago, 5640 South Ellis Avenue, Chicago, IL 60637, USA.ORCID 0000-0001-8171-3640
Fabian ByléhnPritzker School of Molecular Engineering, University of Chicago, 5640 South Ellis Avenue, Chicago, IL 60637, USA.ORCID 0000-0001-9331-6773
Walter AlvaradoPritzker School of Molecular Engineering, University of Chicago, 5640 South Ellis Avenue, Chicago, IL 60637, USA.
Dan MendelsPritzker School of Molecular Engineering, University of Chicago, 5640 South Ellis Avenue, Chicago, IL 60637, USA.
Stuart J RowanPritzker School of Molecular Engineering, University of Chicago, 5640 South Ellis Avenue, Chicago, IL 60637, USA.
Savaş TayPritzker School of Molecular Engineering, University of Chicago, 5640 South Ellis Avenue, Chicago, IL 60637, USA.
Juan J de PabloPritzker School of Molecular Engineering, University of Chicago, 5640 South Ellis Avenue, Chicago, IL 60637, USA.
University of Chicago · USArgonne National Laboratory · US

Funding

Predoctoral Training Program in Chemistry & BiologyT32GM008720 · NIGMS · UNIVERSITY OF CHICAGO · PI PICCIRILLI, JOSEPH ANTHONY · 1999 to 2020
$4.7M
NIGMS NIH HHS T32 GM008720
6 · The paper itself

Abstract

Recently, a high-throughput screen of 1900 clinically used drugs identified masitinib, an orally bioavailable tyrosine kinase inhibitor, as a potential treatment for COVID-19. Masitinib acts as a broad-spectrum inhibitor for human coronaviruses, including SARS-CoV-2 and several of its variants. In this work, we rely on atomistic molecular dynamics simulations with advanced sampling methods to develop a deeper understanding of masitinib's mechanism of M

Indexed as

BenzamidesPiperidinesPyridinesAntiviral AgentsHumansLigandsProtease InhibitorsThiazolesAntiviral AgentsBenzamidesLigandsmasitinibPiperidinesProtease InhibitorsPyridinesThiazolesmasitinib derivativesMpro inhibitorsSARS-CoV-2

Identifiers

PMID37764425
PMCPMC10536273
OpenAlexW4386838669

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.